Anti-cancer immunotherapy drug with reduced side effects and increased therapeutic effects
(National Research Council of Science& Technology) To tackle this issue, a research team led by Dr. Ju Hee Ryu of the Center for Theragnosis at the Korea Institute of Science and Technology (KIST) has developed an anti-cancer prodrug that can improve anti-cancer immunotherapy by reacting only with cancer cells, thereby minimizing the toxicity to normal cells, including immune cells, and boosting patient immunity.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | International Medicine & Public Health | Science | Toxicology